Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Table 3 Race/ethnicity disparities in the use of biologic DMARDs among RA patients in Medicaid

Cohort group	Race/ethnicity	Total, n	Biologic DMARD initiation/switch, n	No biologic DMARD initiation/switch, n	Adjusted OR (95% CI)
Odds of biologic DMARD initiation^a
Early untreated RA, biologic-DMARD-naive group	White, non-Hispanic	23,627	794	22,833	Ref
	Black, non-Hispanic	13,531	275	13,256	0.59 (0.51, 0.68)
	Other non-Hispanic	4824	133	4691	0.88 (0.72, 1.06)
	Hispanic	9875	403	9472	1.24 (1.08, 1.42)
	Total	51,857	1605	50,252	−
Prevalent RA, biologic-DMARD-naive group	White, non-Hispanic	25,537	2570	22,967	Ref
	Black, non-Hispanic	11,171	759	10,412	0.71 (0.61, 0.74)
	Other non-Hispanic	5950	521	5429	0.89 (0.81, 0.99)
	Hispanic	10,853	1219	9634	1.08 (0.99, 1.17)
	Total	53,511	5069	48,442	−
Odds of biologic DMARD switch^a
Prevalent RA, prior biologic DMARD users	White, non-Hispanic	4181	532	3649	Ref
	Black, non-Hispanic	976	99	877	0.71 (0.55, 0.90)
	Other non-Hispanic	836	98	738	1.08 (0.85, 1.41)
	Hispanic	1670	192	1478	0.92 (0.76, 1.12)
	Total	7663	921	6742	−

DMARD disease-modifying antirheumatic drug, RA rheumatoid arthritis. ^aAdjusted for demographics, data source, calendar year, comorbidities, history of medication use, and healthcare utilization in baseline period

ISSN: 1478-6362